Ovatodiolide sensitizes aggressive breast cancer cells to doxorubicin, eliminates their cancer stem cell-like phenotype, and reduces doxorubicin-associated toxicity

Highlights • Ovatodiolide sensitizes triple negative breast cancer cells to doxorubicin anticancer activity. • Sensitization of TNBC cells with Ovatodiolide before Doxorubicin treatment significantly suppresses their metastatic potential in vitro. • Pre-treatment with Ovatodiolide before administration of Doxorubicin eliminates TNBC stem cell-like phenotype. • Ovatodiolide-Doxorubicin sequential administration reduces doxorubicin-associated toxicity in non-tumorigenic cells.